| Literature DB >> 29724056 |
Ze-Jun Wang1, Thomas Heinbockel2.
Abstract
Essential oils and the constituents in them exhibit different pharmacological activities, such as antinociceptive, anxiolytic-like, and anticonvulsant effects. They are widely applied as a complementary therapy for people with anxiety, insomnia, convulsion, pain, and cognitive deficit symptoms through inhalation, oral administration, and aromatherapy. Recent studies show that essential oils are emerging as a promising source for modulation of the GABAergic system and sodium ion channels. This review summarizes the recent findings regarding the pharmacological properties of essential oils and compounds from the oils and the mechanisms underlying their effects. Specifically, the review focuses on the essential oils and their constituents targeting the GABAergic system and sodium channels, and their antinociceptive, anxiolytic, and anticonvulsant properties. Some constituents target transient receptor potential (TRP) channels to exert analgesic effects. Some components could interact with multiple therapeutic target proteins, for example, inhibit the function of sodium channels and, at the same time, activate GABAA receptors. The review concentrates on perspective compounds that could be better candidates for new drug development in the control of pain and anxiety syndromes.Entities:
Keywords: CNS; GABA receptor; analgesics; anticonvulsant; antinociception; anxiolytic; epilepsy; essential oils; pain; sensory neurons; sodium channel; terpenes; transient receptor potential (TRP) channel
Mesh:
Substances:
Year: 2018 PMID: 29724056 PMCID: PMC6099651 DOI: 10.3390/molecules23051061
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
The summary of essential oils from different plants, their pharmacological properties, and mechanism of actions.
| EO Botanical Origins | Administration | Pharmacological Effects | Mechanism of Actions | Authors/Year/Ref. |
|---|---|---|---|---|
|
| anxiolytic effects | not probably mediated through GABA and opioid receptors | Majnooni et al., 2013 [ | |
| pentylenetetrazole-induced convulsion; sedative effect; CNS inhibitory effects | increased GABA level; decreased GABA transaminase | Koo et al., 2003 [ | ||
| analgesic effects | inhibited Na+ channels | Moreira-Lobo et al., 2010 [ | ||
| in vitro | effective antioxidant, radical-scavenging activities, and neuronal protection | inhibited [3H] nicotine binding | Abuhamdah et al., 2015 [ | |
|
| in vitro | antifungal and anti-inflammatory activities | N/A | Abu-Darwish et al., 2015 [ |
|
|
| antinociceptive activity | partially mediated by the opioid system | Anaya-Eugenio et al., 2016 [ |
|
| in vitro | antifungal and anti-inflammatory activities | N/A | Abu-Darwish et al., 2016 [ |
|
|
| peripheral and central antinociceptive activity | N/A | Maham et al., 2014 [ |
|
|
| decreased depression-like behaviors | N/A | Park et al., 2015 [ |
|
|
| increased sleeping time | potentiated GABAA receptors | Hossain et al., 2004 [ |
|
|
| anxiolyticlike activity | serotonergic system (5-HT1A receptors) | Costa et al., 2013 [ |
|
| decreased stress-induced anxiety | tuning synaptic plasticity | Bagetta et al., 2010 [ | |
|
|
| acute anxiolytic activity | N/A | Faturi et al., 2010 [ |
|
|
| increased anxiolytic–antidepressant-like behaviors, and | N/A | Cioanca et al., 2014 [ |
|
|
| anxiolytic-like activity | potentiated GABAA receptor complex | Costa et al., 2011 [ |
|
| anticonvulsant activities | via GABAergic neurotransmission | Silva et al., 2010 [ | |
|
|
| antinociceptive effects | N/A | Déciga-Campos et al., 2017 [ |
|
| sedative and central anesthetic activities | no involvement of the GABAA-BDZ system | Silva et al., 2013 [ | |
|
|
| anxiolytic-like effects | serotonergic system | Chioca et al., 2013 [ |
|
| central anesthetic effect | involvement of the GABAergic system | Heldwein et al., 2012 [ | |
|
| anxiolytic, antidepressant-like effects | suppression of DA activity related to enhanced 5-HTnergic neurons | Komiya et al., 2006 [ | |
|
|
| anti-agitation effects in patients and the depressant effects in in-vitro | inhibited GABA-induced currents | Abuhamdah et al., 2008 [ |
|
| potentiation of valproate-induced anticonvulsant effect | increased in GABAergic response | Raza et al., 2008 [ | |
| Perfume and phytoncid |
| anxiolytic anticonvulsant and sedative activity | potentiating GABAA receptors | Aoshima and Hamamoto, 1999 [ |
|
|
| sedative and anxiolytic-like effects | N/A | Tankam and Tto, 2013 [ |
|
| relaxant and spasmolytic effects | involvement of β-adrenoceptors and calcium channels | Shirole et al., 2015 [ | |
|
| anti-depressant-like effect | modulating DAnergic pathway | Seol et al., 2010 [ | |
|
| local anesthesia | Inhibited sodium channels | Huang et al., 2012 [ | |
|
| anxiogenic-like effects | negative modulation on the GABAergic function | Marin et al., 1998 [ | |
|
| antinociceptive activity | via peripheral nervous excitability blockade | Gonçalves et al., 2017 [ | |
|
| sedatives | N/A | Houghton, 1999 [ |
Note: N/A: not applicable; p.o.: by mouth, oral; sc: subcutaneous injection; i.p.: intraperitoneal injection; INH: inhalation.
The summary of pharmacological properties of constituents from essential oils of different plants targeting Na+ channels and GABAergic system.
| Constituents | Pharmacological Effects | Mechanism of Actions | Authors/Year/Ref. |
|---|---|---|---|
| 1,8-Cineole | antinociceptive, smooth muscle relaxant | reduction of excitability of peripheral neurons by blocking voltage-dependent Na+ current | Ferreira-da-Silva et al., 2015 [ |
| neuronal excitant | hyperexcitability and epileptiform activity in snail neurons by inhibiting potassium channels | Zeraatpisheh and Vatanparast, 2015 [ | |
| 1-Nitro-2-phenylethane | hypnotic, anti-convulsant and anxiolytic effects | N/A | Oyemitan et al., 2013 [ |
| vasorelaxant effects in rat isolated aortic rings | inhibition of contractile events that are clearly independent of Ca2+ influx | Arruda-Barbosa et al., 2014 [ | |
| vasorelaxant effects | N/A | Interaminense et al., 2013 [ | |
| (+)-Borneol | alleviated mechanical hyperalgesia in models of chronic inflammatory and neuropathic pain | enhanced GABAAR-mediated GABAergic transmission | JIang et al., 2015 [ |
| (+)- and (−)-Borneol | analgesia and anesthesia | positive modulation of GABAAR | Granger et al., 2005 [ |
| (+)-Dehydrofukinone | sedative or anesthetic effects | interacted with GABAergic receptors; a suppressor of neuronal excitability | Garlet et al., 2016 [ |
| ( | Anti-stress effect | Zhou et al., 2009 [ | |
| ( | anxiolytic-like effects | N/A | Lima et al., 2013 [ |
| (+)-Dehydrofukinone | sedation, anticonvulsant and anesthesia | potentiated GABAA receptors | Garlet et al., 2017 [ |
| α-asarone | antiepileptic effect | enhanced tonic GABAergic inhibition | Huang et al., 2013 [ |
| antiepileptic effect | Na+ channel blockade and activation of GABAA receptors | Wang ZJ et al., 2014 [ | |
| anticonvulsant | blocked Na+ channel, potentiated GABAA receptors | Wang ZJ et al., 2014 [ | |
| α-(−)-Bisabolol | antinociceptive-like effect | decreased peripheral nerve excitability probably by blockade of voltage-gated Na+ channels | Wang YW et al., 2015 [ |
| α-Pinene | anxiolytic and hypnotic effects | a partial modulator of GABAA receptors and directly binding to the benzodiazepine binding site of GABAA receptor. | Yang et al., 2016 [ |
| β-Citronellol | Hypotensive action | antagonized transmembrane Ca2+ influx from the extracellular milieu to produce myorelaxant actions. | Vasconcelos et al., 2016 [ |
| ( | antimanic-like effects | blockade of voltage-gated Na+ channels; activating TRPV1 and TRPA1 channels | Nogoceke et al., 2016 [ |
| Benzyl benzoate | anxiolytic effect | probably through 5-HTnergic and DAnergic pathways | Alves et al., 2016 [ |
| Carvacrol | antinematodal action | nicotinic acetylcholine receptors and GABA receptors | Trailović et al., 2015 [ |
| analgesic activity | reduced excitability of peripheral neurons; reduced voltage-dependent Na+ current | Joca et al., 2012, 2015 [ | |
| anxiolytic effects in the plus-maze test | involvement with GABAergic transmission | Melo et al., 2010 [ | |
| Estragole | anxiolytic and antimicrobial activities | inhibition of neuronal excitability by blocking Na+ channels | Silva-Alves et al., 2013 [ |
| Eugenol | local analgesic | inhibition of Na+ channels | Vatanparast, 2017 [ |
| analgesic | reduced neuronal hyperexcitability by blocking Na+ currents | Huang et al., 2012 [ | |
| inhibition of action potentials | Moreira-Lobo et al., 2010 [ | ||
| Isopulegol | pentylenetetrazol-induced convulsions | positive modulation of GABAAR and antioxidant properties | Silva et al., 2009 [ |
| Linalool | antinociceptive effect | blocked excitability by decreasing the voltage-dependent Na+ current in dorsal root ganglion neurons | Leal-Cardoso et al., 2010 [ |
| Menthol | analgesia | blocked action potentials in frog sciatic nerves unassociated with TRPM8 activation | Kawasaki et al., 2013 [ |
| Methyleugenol | anticonvulsant, antinociceptive and anesthetic activities | agonist of GABAA receptors in cultured hippocampal neurons | Ding et al., 2014 [ |
| antinociceptive effect | inhibition of NMDA receptor-mediated hyperalgesia via GABAA receptors | Yano et al., 2006 [ | |
| antinociceptive and anesthetic actions | inhibition of Nav1.7 channels | Wang ZJ et al., 2015 [ | |
| Myrtenol and Verbenol | sedative, anxiolytic and anticonvulsive effects | augments phasic and tonic GABAergic inhibition; positive allosteric modulation of GABAA receptors | van Brederode et al., 2016 [ |
| Nerolidol | antinociceptive and anti-inflammatory activity | involvement of the GABAergic system and proinflammatory cytokines | Fonsêca et al., 2016 [ |
| Terpinen-4-ol | anticonvulsant effects | involvement of the GABAergic system, and decrease Na+ current | Nóbrega et al., 2014 [ |
| Thujone | muscle spasms and convulsions | GABA receptor antagonist | Mariani et al., 2016 [ |
| Thymol | antinociception | nerve conduction inhibition; activated TRPA1 channels; a positive allosteric modulator of human GABAAR | Xu et al., 2015 [ |
| Thymoquinone | anticonvulsant effects | opioid receptor-mediated increase in GABAergic tone | Hosseinzadeh and Parvardeh, 2004 [ |
Note: N/A: not applicable.
Figure 1The chemical structures of terpenes with analgesic properties targeting the Na+ and transient receptor potential (TRP) channels.
Figure 2The chemical structures of terpenes with analgesic and anticonvulsant properties targeting GABAA receptors.
Figure 3The chemical structures of phenylpropanoid derivatives with analgesic properties.
Figure 4The chemical structures of terpenes with anxiolytic targeting GABAA receptors.
Figure 5The non-terpene constituents with anticonvulsant and anxiolytic activities.
Figure 6The terpenes acting on GABAA receptors as antagonists.